Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?

The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.

(2017) A. J. Montero et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

(2015) John R. Mackey et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

(2014) Mark J. Clemons et al.   BREAST CANCER RESEARCH AND TREATMENT

A systematic review of bevacizumab efficacy in breast cancer

(2014) Iben Kümler et al.   CANCER TREATMENT REVIEWS

Hallmarks of triple negative breast cancer emerging at last?

(2014) Rosa Bernardi et al.   CELL RESEARCH

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

(2014) Igor Puzanov et al.   INVESTIGATIONAL NEW DRUGS

Harnessing the immune system for the treatment of breast cancer

(2014) Xinguo Jiang   Journal of Zhejiang University-SCIENCE B

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

(2014) Joseph Gligorov et al.   LANCET ONCOLOGY

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

(2013) D. W. Miles et al.   ANNALS OF ONCOLOGY

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer

(2013) Xiaoyong Fu et al.   BREAST

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

(2013) Stephen R. D. Johnston et al.   BREAST CANCER RESEARCH AND TREATMENT

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

(2013) L. S. Schwartzberg et al.   CLINICAL CANCER RESEARCH

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

(2013) David M. Hyams et al.   INVESTIGATIONAL NEW DRUGS

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

(2013) Lida A. Mina et al.   INVESTIGATIONAL NEW DRUGS

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

(2013) John P. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

(2013) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGFA and tumour angiogenesis

(2013) L. Claesson-Welsh et al.   JOURNAL OF INTERNAL MEDICINE

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

(2013) Istvan Lang et al.   LANCET ONCOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

(2013) José Baselga et al.   Trials

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

(2012) Denise A. Yardley et al.   BREAST CANCER RESEARCH AND TREATMENT

North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

(2012) Kostandinos Sideras et al.   Clinical Breast Cancer

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours

(2012) Ahmad Awada et al.   EUROPEAN JOURNAL OF CANCER

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

(2012) William J. Gradishar et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

(2012) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer

(2012) Robert S. Kerbel   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

(2012) Harry D. Bear et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

(2012) José R. Rossari et al.   Journal of Oncology

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

(2011) Kenjiro Aogi et al.   BREAST CANCER RESEARCH AND TREATMENT

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial

(2011) G. Mariani et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

(2011) Xavier Pivot et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

(2011) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial

(2011) Ahmad Awada et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

(2011) Miguel Martin et al.   LANCET ONCOLOGY

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

(2010) E. L. Mayer et al.   ANNALS OF ONCOLOGY

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

(2010) I. E. Smith et al.   ANNALS OF ONCOLOGY

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

(2010) H. Wildiers et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

(2010) Claudine Isaacs et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2

(2010) Xiao-Feng Le et al.   CELL CYCLE

Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

(2010) Maximilian Merz et al.   EUROPEAN JOURNAL OF CANCER

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

(2010) Katalin Boér et al.   INVESTIGATIONAL NEW DRUGS

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

(2010) Christopher J. Sweeney et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

(2010) S. K. Taylor et al.   ONCOLOGIST

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

(2009) Giulia Bianchi et al.   ANTI-CANCER DRUGS

Why are tumour blood vessels abnormal and why is it important to know?

(2009) J A Nagy et al.   BRITISH JOURNAL OF CANCER

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

(2009) Konstantin J. Dedes et al.   EUROPEAN JOURNAL OF CANCER

From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage

(2008) S. Giordano et al.   CURRENT MEDICINAL CHEMISTRY

High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer

(2008) Sriparna Ghosh et al.   HUMAN PATHOLOGY

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

(2008) Alvaro Moreno-Aspitia et al.   JOURNAL OF CLINICAL ONCOLOGY

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

(2008) L. Dal Lago et al.   ONCOLOGIST

Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead

(2007) V. W.M. van Hinsbergh et al.   CARDIOVASCULAR RESEARCH